vs
FiscalNote Holdings, Inc.（NOTE）与SUTRO BIOPHARMA, INC.（STRO）财务数据对比。点击上方公司名可切换其他公司
FiscalNote Holdings, Inc.的季度营收约是SUTRO BIOPHARMA, INC.的1.9倍（$22.2M vs $11.6M），SUTRO BIOPHARMA, INC.同比增速更快（-21.4% vs -24.7%），过去两年SUTRO BIOPHARMA, INC.的营收复合增速更高（-5.4% vs -16.8%）
FiscalNote Holdings, Inc.（常称FiscalNote）是一家上市的软件数据与传媒企业，总部位于美国华盛顿特区，2013年由三位创始人创立。核心业务为通过政府关系管理服务FiscalNote GRM提供软件工具、平台、数据服务与资讯，同时依托人工智能平台分析美国待审议法案相关内容。
Sutro Biopharma是一家上市生物科技公司，总部位于加州南旧金山，专注于临床阶段药物的研发、开发与生产。公司依托自主专有的无细胞蛋白质合成平台，结合蛋白质工程与理性设计技术开发肿瘤治疗药物。公司2003年成立时名为Fundamental Applied Biology，2009年改用现名。
NOTE vs STRO — 直观对比
营收规模更大
NOTE
是对方的1.9倍
$11.6M
营收增速更快
STRO
高出3.3%
-24.7%
两年增速更快
STRO
近两年复合增速
-16.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.2M | $11.6M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | -83.7% | — |
| 净利率 | — | — |
| 营收同比 | -24.7% | -21.4% |
| 净利润同比 | — | 35.4% |
| 每股收益（稀释后） | $-2.81 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NOTESTRO
| Q4 25 | $22.2M | $11.6M | ||
| Q3 25 | $22.4M | $9.7M | ||
| Q2 25 | $23.3M | $63.7M | ||
| Q1 25 | $27.5M | $17.4M | ||
| Q4 24 | $29.5M | $14.8M | ||
| Q3 24 | $29.4M | $8.5M | ||
| Q2 24 | $29.2M | $25.7M | ||
| Q1 24 | $32.1M | $13.0M |
净利润NOTESTRO
| Q4 25 | — | — | ||
| Q3 25 | $-24.9M | $-56.9M | ||
| Q2 25 | $-13.3M | $-11.5M | ||
| Q1 25 | $-4.3M | $-76.0M | ||
| Q4 24 | — | $-72.4M | ||
| Q3 24 | $-14.9M | $-48.8M | ||
| Q2 24 | $-12.8M | $-48.0M | ||
| Q1 24 | $50.6M | $-58.2M |
营业利润率NOTESTRO
| Q4 25 | -83.7% | — | ||
| Q3 25 | -43.4% | -499.9% | ||
| Q2 25 | -31.9% | -5.2% | ||
| Q1 25 | -50.0% | -393.8% | ||
| Q4 24 | -19.4% | -440.7% | ||
| Q3 24 | -23.1% | -797.2% | ||
| Q2 24 | -27.2% | -189.4% | ||
| Q1 24 | -35.6% | -435.0% |
净利率NOTESTRO
| Q4 25 | — | — | ||
| Q3 25 | -110.8% | -586.6% | ||
| Q2 25 | -57.0% | -18.0% | ||
| Q1 25 | -15.4% | -436.6% | ||
| Q4 24 | — | -489.2% | ||
| Q3 24 | -50.7% | -572.6% | ||
| Q2 24 | -43.6% | -186.8% | ||
| Q1 24 | 157.6% | -447.5% |
每股收益（稀释后）NOTESTRO
| Q4 25 | $-2.81 | — | ||
| Q3 25 | $-1.73 | $-0.67 | ||
| Q2 25 | $-0.08 | $-0.14 | ||
| Q1 25 | $-0.03 | $-0.91 | ||
| Q4 24 | $1.88 | $-27.63 | ||
| Q3 24 | $-1.33 | $-0.59 | ||
| Q2 24 | $-0.09 | $-0.59 | ||
| Q1 24 | $0.37 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.3M | $141.4M |
| 总债务越低越好 | $128.4M | — |
| 股东权益账面价值 | $62.0M | $-132.5M |
| 总资产 | $255.1M | $173.8M |
| 负债/权益比越低杠杆越低 | 2.07× | — |
8季度趋势，按日历期对齐
现金及短期投资NOTESTRO
| Q4 25 | $26.3M | $141.4M | ||
| Q3 25 | $31.2M | $167.6M | ||
| Q2 25 | $38.5M | $205.1M | ||
| Q1 25 | $46.3M | $249.0M | ||
| Q4 24 | $34.6M | $316.9M | ||
| Q3 24 | $32.7M | $388.3M | ||
| Q2 24 | $37.7M | $375.6M | ||
| Q1 24 | $43.6M | $267.6M |
总债务NOTESTRO
| Q4 25 | $128.4M | — | ||
| Q3 25 | $131.5M | — | ||
| Q2 25 | $116.7M | — | ||
| Q1 25 | $118.0M | — | ||
| Q4 24 | $147.1M | — | ||
| Q3 24 | $152.2M | — | ||
| Q2 24 | $145.9M | — | ||
| Q1 24 | $153.0M | — |
股东权益NOTESTRO
| Q4 25 | $62.0M | $-132.5M | ||
| Q3 25 | $75.5M | $-87.3M | ||
| Q2 25 | $95.1M | $-32.1M | ||
| Q1 25 | $98.7M | $-25.8M | ||
| Q4 24 | $97.8M | $44.6M | ||
| Q3 24 | $98.5M | $111.2M | ||
| Q2 24 | $106.9M | $152.2M | ||
| Q1 24 | $106.1M | $98.0M |
总资产NOTESTRO
| Q4 25 | $255.1M | $173.8M | ||
| Q3 25 | $273.9M | $209.7M | ||
| Q2 25 | $288.3M | $262.4M | ||
| Q1 25 | $299.7M | $321.4M | ||
| Q4 24 | $326.2M | $387.2M | ||
| Q3 24 | $337.9M | $451.8M | ||
| Q2 24 | $346.3M | $489.0M | ||
| Q1 24 | $357.8M | $403.4M |
负债/权益比NOTESTRO
| Q4 25 | 2.07× | — | ||
| Q3 25 | 1.74× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.20× | — | ||
| Q4 24 | 1.50× | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 1.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-279.0K | $-177.2M |
| 自由现金流经营现金流 - 资本支出 | $-1.9M | — |
| 自由现金流率自由现金流/营收 | -8.7% | — |
| 资本支出强度资本支出/营收 | 7.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.6M | — |
8季度趋势，按日历期对齐
经营现金流NOTESTRO
| Q4 25 | $-279.0K | $-177.2M | ||
| Q3 25 | $-8.3M | $-38.2M | ||
| Q2 25 | $-6.2M | $-44.7M | ||
| Q1 25 | $3.3M | $-67.9M | ||
| Q4 24 | $-1.3M | $-71.7M | ||
| Q3 24 | $-3.0M | $-64.5M | ||
| Q2 24 | $-3.7M | $9.5M | ||
| Q1 24 | $2.7M | $-64.7M |
自由现金流NOTESTRO
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $-10.4M | — | ||
| Q2 25 | $-7.7M | — | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $-3.4M | — | ||
| Q3 24 | $-5.4M | — | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $1.0M | — |
自由现金流率NOTESTRO
| Q4 25 | -8.7% | — | ||
| Q3 25 | -46.2% | — | ||
| Q2 25 | -33.0% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | -11.4% | — | ||
| Q3 24 | -18.4% | — | ||
| Q2 24 | -22.1% | — | ||
| Q1 24 | 3.3% | — |
资本支出强度NOTESTRO
| Q4 25 | 7.4% | — | ||
| Q3 25 | 9.3% | — | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | 7.2% | — | ||
| Q4 24 | 6.8% | — | ||
| Q3 24 | 8.3% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 5.3% | — |
现金转化率NOTESTRO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NOTE
| Subscription | $21.2M | 95% |
| Advisory Advertising And Other | $1.0M | 5% |
STRO
暂无分部数据
